Enhanced leakiness of the blood–brain barrier has been associated with neurodegenerative disease, and assessing this leakiness has even been suggested as a possible method for early diagnosis of such disease. In light of the recent promising results from the lecanemab therapy for Alzheimer’s disease, CLI caught up with Dr Fiona McLean (University of Dundee, UK) […]
Awareness of the utility of wastewater for epidemiology was raised during the recent COVID-19 pandemic. CLI caught up with Dr Andrew Singer (UK Centre for Ecology & Hydrology) to find out more about the development of wastewater-based epidemiology and what it can do for us.
In September, the companies Eisai and Biogen announced good news about the results of their ‘Clarity AD’ clinical trial of their drug lecanemab (https://www.eisai.com/news/2022/news202271.html).
In their aim to support researchers and clinicians, companies such as Thermo Fisher Scientific are also at the forefront of their own R&D. CLI caught up with Dr Edward Goucher, Senior Manager of Business Development, to discuss their new developments.
Frinculescu A, Coombes G, Shine T et al. Drug Test Anal 2022;doi:10.1002/dta.3277 Increasing popularity and known shortfalls in the regulation of electronic cigarettes (ECs) emphasizes the urgent need for closer content monitoring and for comprehensible information on their possible health effects.
by Xijun Min, Dr Yan Li, Liuyan Chen, Chengwei Yao, Dr Xi Qin As a traditional tumour marker for the diagnosis of early primary hepatic carcinoma (PHC), alpha fetoprotein (AFP) has a low positive rate. Serum glypican 3 (GPC3) is a novel biomarker, and the combined examination of GPC3 and AFP will provide a new […]
by Dr Cherie Ng and Dr Chaim Putterman Lupus nephritis is an immune-mediated glomerulonephritis that causes significant morbidity and mortality in patients with systemic lupus erythematous, a multisystem autoimmune disease. Non-invasive biomarkers are necessary to track disease and treatment response. Urinary ALCAM is a potential biomarker that samples the kidney and is relevant to the […]
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. CLI caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
Those of you who regularly cast an eye over the Editor’s Letter in CLI will know that we have been closely following the story of the development of a sebum-based biomarker test to diagnose Parkinson’s disease (PD; Editor’s letters in the Feb/March issues of CLI in 2018 and 2021).
In spite of all the efforts over many years and decades to reduce malaria infection and deaths, the latest data from the World Health Organization (WHO) still show that in 2020 there were 241 million cases and 627 000 deaths. Of which, 95% of cases and 96% of deaths were in sub-Saharan Africa; 80% of […]
November 2024
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.